The use of dopamine agonists in very elderly patients with Parkinson's disease

Movement Disorders

Volumn 15, Issue 4, 2000, Pages 664-668

  Shulman, Lisa M ^a   Minagar, Alireza ^a   Rabinstein, Alejandro ^a   Weiner, William J ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

Agonists; Elderly; Parkinson

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT; PERGOLIDE; PRAMIPEXOLE; ROPINIROLE;

AGED; ARTICLE; CONTROLLED STUDY; DATA BASE; DOSE RESPONSE; DRUG TOLERABILITY; DYSKINESIA; ELDERLY CARE; FATIGUE; FEMALE; GAIT DISORDER; HALLUCINATION; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DETERIORATION; MOTOR DYSFUNCTION; NAUSEA; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SOMNOLENCE; TREATMENT OUTCOME; TREMOR; VOMITING;

AGED; AGED, 80 AND OVER; ANTIPARKINSON AGENTS; DOPAMINE AGONISTS; FEMALE; HUMANS; MALE; NEUROLOGIC EXAMINATION; PARKINSON DISEASE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 0033926351     PISSN: 08853185     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8257(200007)15:4<664::AID-MDS1010>3.0.CO;2-D     Document Type: Article

References (34)

1. Marsden CD. Parkinson's disease. J Neurol Neurosurg Psychiatry 1994;57:672-681.
2. Lusis SA. Pathophysiology and management of idiopathic Parkinson's disease. Journal of Neuroscience Nursing 1997;29:21-31.
3. Playfer JR. Parkinson's disease. Postgrad Med J 1997;73:257-264.
4. Robertson DR, Wood ND, Everest H, et al. The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. Br J Clin Pharmacol 1989;28:61-69.
5. Contin M, Riva R, Martinelli P, Albani F, Baruzzi A. Effect of age on the pharmacokinetics of oral levodopa in patients with Parkinson's disease. Eur J Clin Pharmacol 1991;41:463-466.
6. Saint-Cyr JA, Taylor AE, Lang AE. Neuropsychological and psychiatric side effects in the treatment of Parkinson's disease. Neurology 1993;43(suppl 6):S47-S52.
7. Joseph CL, Siple J, McWhorter K, Camicioli R. Adverse reactions to controlled release levodopa/carbidopa in older persons: case reports. J Am Geriatr Soc 1995;43:47-50.
8. De Smet Y, Ruberg M, Serdaru M, Dubois B, Lhermitte F, Agid Y. Confusion, dementia, and anticholinergics in Parkinson's disease. J Neurol Neurosurg Psychiatry 1982;45:1161-1164.
9. Perderzoli M, Girotti F, Scigliano G, Aiello G, Carella F, Caraceni T. L-Dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983;33:1518-1522.
10. Mitchell SL, Sullivan EA, Lipsitz LA. Exclusion of elderly subjects from clinical trials for Parkinson's disease. Arch Neurol 1997; 54:1393-1398.
11. Hietanen M, Teravainen H. The effect of age disease onset on neuropsychological performance in Parkinson's disease. J Neurol Neurosurg Psychiatry 1991;54:780-782.
12. Rajput AH, Pahwa R, Pahwa P, Rajput A. Prognostic significance of the mode of onset in parkinsonism. Neurology 1993;43:829-830.
13. Goetz CG, Tanner CM, Stebbins GT, Buchman AS. Risk factors for progression in Parkinson's disease. Neurology 1988;38:1841-1844.
14. Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD. Effect of age at onset on the progression and mortality in Parkinson's disease. Neurology 1990;39:1187-1190.
15. Jankovic J, McDermott M, Carter J, et al. Variable expression of Parkinson's disease: a baseline analysis of the DATATOP cohort. Neurology 1990;40:1529-1534.
16. Birkmayer W, Reiderer WP, Youdim MBH. Distinction between benign and malignant type of Parkinson's disease. Clin Neurol Neurosurg 1979;82:158-164.
17. Mayeux R, Derano J, Hemenegildo N, et al. A population-based investigation of Parkinson's disease with and without dementia: relationship to age and gender. Arch Neurol 1992;49:534-536.
18. Mutch WJ, Dingwall-Fordyce I, Downie AW, et al. Parkinson's disease in a Scottish city. BMJ 1986;292:534-536.
19. Mayeux R, Chen J, Mirabello E, et al. An estimate of the incidence of dementia in Parkinson's disease. Neurology 1993;43:1690-1692.
20. Cummings JL. Behavioral complications of drug treatment of Parkinson's disease. J Am Geriatr Soc 1991;39:708-716.
21. Avron J, Gurwitz JH. Principles of pharmacology. In: Cassel C, Riesenberg D, ed. Textbook of Geriatric Medicine. New York, NY: Springer-Verlag, 1990:299-310.
22. Pederzoli M, Girotti F, Scigliano G, et al. L-Dopa long-term treatment in Parkinson's disease: age-related side effects. Neurology 1983;33:1518-1522.
23. Mawdsley C. Treatment of parkinsonism with levodopa. BMJ 1970;1:331-337.
24. Wilson JA, Smith RG. The prevalence and aetiology of long-term L-dopa side-effects in elderly parkinsonian patients. Age Ageing 1989;18:11-16.
25. Tanner CM, Vogel C, Goetz CG, et al. Hallucinations in Parkinson's disease: a population study. [Abstract]. Ann Neurol 1983;14: 136.
26. Parkinson Study Group. Safety and efficacy of pramipexole in early Parkinson's disease. JAMA 1997;278:125-130.
27. Shannon KM, Bennett JP, Friedman JH, Pramipexole Study Group. Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. Neurology 1997;49:724-728.
28. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49:393-399.
29. Parkes JD, Debono AG, Marsden CD. Bromocriptine in parkinsonism: long-term treatment, dose response, and comparison with levodopa. J Neurol Neurosurg Psychiatry 1976;39:1101-1108.
30. Jankovic J. Long-term study of pergolide in Parkinson's disease. Neurology 1985;35:296-299.
31. Diamond SG, Markham CH, Treciokas LJ. Double-blind trial of pergolide for Parkinson's disease. Neurology 1985;35:291-295.
32. Gran U. Bromocriptine versus placebo in levodopa treated patients with Parkinson's disease. Acta Neural Scand 1977;56:269-273.
33. Factor S, Sanchez-Ramos J, Weiner WJ. Open-label trial of pergolide in patients failing bromocriptine treatment. J Neural Neurosurg Psychiatry 1988;51:529-533.
34. Weiner WJ, Factor SA, Jankovic J, et al. The long-term safety and efficacy of pramipexole in advanced Parkinson's disease. Neurology 1999;52(suppl 2):407-408.